The novelty of OCPAM lies in its dual-modality design, which integrates the high spatial resolution of optical coherence tomography (OCT) with the molecular specificity and penetration depth afforded by photoacoustic microscopy (PAM). OCT alone, while exceptional for capturing microstructural details, is often limited by poor chemical contrast and penetration depth in dense tissue. PAM complements this by employing pulsed laser excitation to generate ultrasonic waves via the photoacoustic effect, thus providing functional and molecular information that is otherwise invisible to traditional optical imaging. This fusion enables comprehensive visualization of cellular morphology co-registered with biochemical signatures, all in 3D.

Central to the significance of this technique is its application to three-dimensional cancer models developed from patient-derived organoids. These organoids are miniature, self-organized tumor-like tissue cultures that recapitulate key aspects of in vivo tumor microenvironments and heterogeneity. Historically, studying these 3D models has been hampered by the lack of imaging technologies that can delve deep into the tissue while maintaining high resolution and contrast. OCPAM bridges this gap, revealing intricate vascular structures, cellular arrangements, and biochemical landscapes crucial for understanding tumor biology and treatment response.

The researchers further enhance the utility of OCPAM through the integration of artificial intelligence-assisted analysis specifically tailored for organoid imaging. This AI framework automates the segmentation, classification, and quantification of various cellular and structural features within the complex 3D datasets. By combining advanced machine learning algorithms with rich multimodal imaging data, the system provides rapid, objective, and reproducible assessments, significantly accelerating data processing times and reducing observer bias—challenges that have long plagued manual histological examination.

From a technical standpoint, the OCPAM system employs a dual-laser configuration synchronized with an ultra-high sensitivity ultrasonic transducer array. The optical coherence module operates in the near-infrared spectrum, facilitating millimeter-scale imaging depths with micrometer lateral resolution. The photoacoustic component exploits a tunable laser source to excite chromophores such as hemoglobin and melanin, enabling real-time visualization of vascularization and pigmentation changes within the tumor microenvironment. Furthermore, the system’s scanning mechanism harnesses precision galvo mirrors, allowing rapid volumetric data acquisition at video-rate speeds without compromising image quality.

The integration of these modalities involves careful calibration to ensure co-registration of OCT and PAM images, aligning anatomical features with functional signals seamlessly. Post-acquisition, the volumetric datasets undergo advanced image reconstruction algorithms to enhance contrast and minimize artifacts, thereby maximizing diagnostic value. The accompanying AI pipeline was trained on extensive datasets comprising various organoid types and tumor compositions, enabling it to reliably discern cancerous from non-cancerous regions and extract quantitative metrics predictive of tumor aggressiveness and treatment sensitivity.

One of the striking advantages of OCPAM demonstrated in the study is its capability to monitor dynamic tumor behaviors in vitro over extended periods. Researchers showed that this platform could non-invasively track morphological changes, angiogenesis, and hypoxia-driven molecular shifts within organoids subjected to different chemotherapeutic agents. This opens new avenues for personalized medicine by facilitating real-time evaluation of drug efficacy at a cellular level, potentially guiding tailored therapeutic strategies that minimize toxicity while maximizing response.

In addition to cancer research, the versatility of OCPAM suggests broad applicability across biomedical fields requiring detailed 3D imaging of complex tissues. For example, its ability to visualize vascular networks and cellular heterogeneity could prove invaluable for studying developmental biology, tissue engineering, and neurodegenerative diseases where conventional imaging falls short. The system’s non-destructive nature further permits longitudinal studies on the same sample, preserving precious biological resources and enabling temporal investigations previously impractical.

The implications for clinical practice are equally promising. While current histopathological diagnosis relies heavily on invasive biopsies and time-consuming slide-based analysis, OCPAM could ultimately provide in situ, label-free imaging of biopsy specimens or surgical margins, aiding surgeons and pathologists with rapid, high-resolution feedback. Combined with AI-driven interpretation, this technology could reduce diagnostic errors, improve accuracy, and accelerate decision-making in oncologic care. The prospect of translating such a platform to bedside or intraoperative use could revolutionize cancer management paradigms.

The collaborative effort behind OCPAM involved multidisciplinary expertise spanning optical engineering, biomedical imaging, computational science, and oncology. This convergence underscores the growing recognition of cross-disciplinary approaches as key drivers of innovation. By uniting these domains, the team crafted a suite of solutions addressing longstanding challenges in tumor imaging—from fundamental physical constraints to practical hurdles in data analysis. Their success exemplifies the kind of integrative research that will undoubtedly shape the future landscape of medical technology.

Challenges remain, however, before OCPAM can be fully integrated into routine laboratory or clinical workflows. The complexity and cost of the dual-modality hardware may limit initial accessibility, necessitating further optimization and cost-reduction efforts. Moreover, comprehensive validation studies across diverse tumor types, including in vivo models and human clinical samples, are critical to establish robustness and generalizability. The AI algorithms also require ongoing refinement to adapt to novel imaging contexts and improvement in interpretability for clinical adoption.

Looking forward, the authors envision expanding the spectral capabilities of OCPAM to target multiple endogenous and exogenous contrast agents, further enriching molecular imaging capabilities. Coupling this with real-time AI decision support platforms could enable truly autonomous analysis pipelines capable of identifying subtle pathological changes earlier than currently possible. Integration with other imaging modalities such as fluorescence or Raman spectroscopy may also enhance diagnostic confidence by providing complementary biochemical insights.

In conclusion, the advent of Optical Coherence Photoacoustic Microscopy combined with AI-assisted organoid analysis marks a monumental step forward in cancer imaging technology. This hybrid approach addresses many of the limitations inherent to existing methods, offering detailed, multi-scale visualization and functional assessment of tumor structures in physiologically relevant 3D models. The ability to non-invasively probe tumor microenvironments with high resolution and rapid processing heralds new opportunities for understanding cancer progression, screening therapeutic responses, and eventually improving patient outcomes. As research and development continue, OCPAM holds immense potential to become a cornerstone platform in the era of precision oncology and beyond.

Subject of Research: The development and application of Optical Coherence Photoacoustic Microscopy (OCPAM) for high-resolution 3D imaging of cancer organoids combined with AI-assisted analysis to enhance understanding and evaluation of tumor biology and drug response.

Article Title: Optical coherence photoacoustic microscopy for 3D cancer model imaging with AI-assisted organoid analysis

Article References:
Deloria, A.J., Csiszar, A., Deng, S. et al. Optical coherence photoacoustic microscopy for 3D cancer model imaging with AI-assisted organoid analysis. Light Sci Appl 15, 106 (2026). https://doi.org/10.1038/s41377-025-02177-2

Image Credits: AI Generated

DOI: 05 February 2026

The research being conducted represents a transformative shift in cancer therapy, moving away from traditional treatments that often come with a multitude of adverse effects to more targeted approaches that specifically aim to kill tumor cells. Dr. Lincoln Stein, the Acting Scientific Director at OICR, emphasizes the importance of these innovative projects. He notes that Ontario has carved out a reputation as a leader in the global fight against cancer, and these new research endeavors have the potential to significantly improve patient outcomes. The use of advanced technologies and an emphasis on understanding cancer biology underpins the approach that these teams are taking.

One notable project, led by Dr. Jinqiang Hou and Dr. Guillem Dayer from the Thunder Bay Regional Health Research Institute, is focused on cervical cancer, a disease that ranks third among cancers affecting women aged 20 to 39 worldwide. The researchers are developing a unique hybrid molecule that selectively targets and destroys cancer cells while sparing healthy tissue. Claiming that their approach acts like a guided missile, they believe this could herald a new era for cervical cancer treatment where side effects are minimized, allowing patients to maintain a better quality of life during therapy.

In parallel, Dr. Iacovos Michael and Dr. Masoud Vedadi from Sunnybrook Research Institute are investigating the challenges posed by cancer metastasis and treatment resistance. These two complications are often the leading causes of cancer-related mortality. Their research, fueled by CTIP funding, aims to leverage new findings surrounding a protein central to such resistance, aiming to develop drugs that can effectively interrupt its function. By elucidating the role of this protein in cancer progression, they hope to pave the way for groundbreaking therapies that increase both survival durations and quality of life for patients battling this devastating disease.

Meanwhile, Dr. Valentina Evdokimova and Dr. Laszlo Radvanyi from the University of Toronto are delving into lesser-known aspects of the human genome, referred to as the “dark matter.” Their focus is on endogenous retroviruses, which were once considered functionally inept but are now being scrutinized for their potential role in cancer. The goal of their research is to create a validated screening platform that identifies these viral elements, ultimately aiming to discover therapeutic options that can halt cancer progression or reduce immunosuppression in patients.

The research team led by Dr. Anthony Rullo from McMaster University is exploring an innovative breast cancer therapy that aims to activate the immune system to combat tumors. They have developed a synthetic covalent antibody mimic that bridges immune cells and tumor cells, leveraging the body’s natural defenses against cancer while simultaneously minimizing the side effects typically associated with conventional chemotherapy treatments. This cutting-edge strategy could represent a significant evolution in immunotherapeutic approaches, offering hope for breast cancer patients who lack viable alternative treatments.

In a separate, yet equally vital, initiative, Dr. Rima Al-awar and her collaborators at OICR are investigating chemical compounds designed to combat the overwhelming growth of cancerous cells by inhibiting the KRAS protein. Known for its role in cancer cell resistance, traditional KRAS inhibitors often fail in treatment scenarios. The innovative compounds being tested in this study aim to circumvent this resistance by employing a fundamentally different mechanism, thus opening the door to new cancer treatment strategies that could vastly improve patient prognosis.

The diversity of these projects highlights the multifaceted approach that Ontario researchers are taking in the fight against cancer. By employing various cutting-edge methodologies and tapping into unique biological insights, they are collectively working towards the common goal of creating novel therapies that promise to revolutionize cancer treatment. The OICR’s commitment to fostering such innovative research initiatives underscores the importance of continued investment in cancer discovery programs.

The CTIP awards play a pivotal role in accelerating the translation of scientific discoveries into practical and effective cancer therapeutics. Applications for CTIP funding are rigorously reviewed by a committee composed of experienced professionals from both academic and industrial backgrounds. This comprehensive evaluation ensures that the supported studies not only have the potential for scientific innovation but also the capacity to make impactful contributions to patient care.

As Ontario positions itself as a leader in the global cancer research landscape, the commitment of local researchers to push the boundaries of what is possible in treatment continues to yield promising results. The collaborative efforts of these dedicated teams, skilled in various specialties, signify a coordinated endeavor to combat the harrowing effects of cancer and provide patients with the hope of healing.

In light of these strides forward in cancer research, Ontario’s Minister of Colleges, Universities, Research Excellence and Security, Nolan Quinn, expressed the province’s pride in its contributions to the field of cancer treatment. By securing financial backing for the OICR and its initiatives, the government aims to facilitate the ongoing discovery of new, effective treatments that not only enhance longevity but also improve health outcomes for those afflicted by cancer.

As these transformative research projects unfold, the potential for breakthroughs and innovations in cancer therapy becomes increasingly tangible. The dedication of researchers and the strategic support from OICR indicate that the future of cancer treatment may very well lie in the hands of these pioneering investigations. The confluence of novel drug discovery and the nuanced understanding of cancer biology heralds a new chapter in the pursuit of effective cancer therapies.

Subject of Research: Development of next-generation cancer therapeutics
Article Title: Ontario Unleashes Innovative Cancer Research Initiatives
News Publication Date: April 3, 2025
Web References: OICR’s Cancer Therapeutics Innovation Pipeline
References: N/A
Image Credits: N/A

Keywords: Cancer research, drug discovery, immunotherapy, therapeutic innovation, Ontario Institute for Cancer Research, cervical cancer, drug resistance, endogenous retroviruses, KRAS inhibitors.